Intellia Therapeutics (NTLA) – Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of Intellia Therapeutics (NASDAQ: NTLA) recently:

• 10/28/2025 – Intellia Therapeutics had its price target lowered by analysts at JMP Securities from $33.00 to $29.00. They now have a “market outperform” rating on the stock.
• 10/28/2025 – Intellia Therapeutics was given a new $14.50 price target on by analysts at Sanford C. Bernstein.
• 10/28/2025 – Intellia Therapeutics had its price target lowered by analysts at Barclays PLC from $26.00 to $24.00. They now have an “overweight” rating on the stock.
• 10/28/2025 – Intellia Therapeutics had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/28/2025 – Intellia Therapeutics was downgraded by analysts at Sanford C. Bernstein from an “outperform” rating to a “market perform” rating. They now have a $14.50 price target on the stock, up previously from $14.00.
• 10/28/2025 – Intellia Therapeutics was given a new $14.50 price target on by analysts at Tudor Pickering.
• 10/28/2025 – Intellia Therapeutics had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $14.00 price target on the stock, down previously from $21.00.
• 10/28/2025 – Intellia Therapeutics was downgraded by analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating. They now have a $14.00 price target on the stock, down previously from $21.00.
• 10/28/2025 – Intellia Therapeutics had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $17.00 price target on the stock, down previously from $45.00.
• 10/27/2025 – Intellia Therapeutics was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating.
• 10/27/2025 – Intellia Therapeutics had its price target lowered by analysts at HC Wainwright from $30.00 to $25.00. They now have a “buy” rating on the stock.
• 10/27/2025 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
• 10/27/2025 – Intellia Therapeutics was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 10/27/2025 – Intellia Therapeutics was downgraded by analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating.
• 10/27/2025 – Intellia Therapeutics had its price target lowered by analysts at Bank of America Corporation from $36.00 to $30.00. They now have a “buy” rating on the stock.
• 10/27/2025 – Intellia Therapeutics had its price target lowered by analysts at Chardan Capital from $60.00 to $48.00. They now have a “buy” rating on the stock.
• 10/8/2025 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Intellia Therapeutics was upgraded by analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating. They now have a $33.00 price target on the stock.
• 10/6/2025 – Intellia Therapeutics was upgraded by analysts at JMP Securities from a “market perform” rating to a “market outperform” rating. They now have a $33.00 price target on the stock.
• 9/27/2025 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/19/2025 – Intellia Therapeutics had its “market perform” rating reaffirmed by analysts at JMP Securities.
• 9/19/2025 – Intellia Therapeutics had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a “buy” rating on the stock.
• 9/6/2025 – Intellia Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Transactions at Intellia Therapeutics

In related news, Director William J. Chase purchased 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the purchase, the director owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their position. The SEC filing for this sale provides additional information. 3.10% of the stock is currently owned by corporate insiders.

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.